Balloon occlusion hepatic arterial infusion chemotherapy for treating unresectable hepatocellular carcinoma complicated with arterioportal fistula
10.13929/j.issn.1672-8475.2024.08.005
- VernacularTitle:球囊阻断肝动脉灌注化疗用于不可切除肝细胞癌合并肝动脉-门静脉瘘
- Author:
Jianfei LIU
1
;
Feng WANG
;
Feng LI
Author Information
1. 大连医科大学附属第一医院介入治疗科,辽宁 大连 116011
- Keywords:
liver neoplasms;
arteriovenous fistula;
chemotherapy,cancer,regional perfusion;
balloon occlusion
- From:
Chinese Journal of Interventional Imaging and Therapy
2024;21(8):463-467
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy and safety of balloon occlusion hepatic arterial infusion chemotherapy(b-HAIC)for treating unresectable hepatocellular carcinoma(HCC)complicated with hepatic arterioportal fistula(HAPF).Methods Eight patients with unresectable HCC complicated with HAPF who underwent FOLFOX b-HAIC were retrospectively enrolled.The technical success rate and b-HAIC related adverse events were recorded,and the efficacy was evaluated.Results Totally 17 times b-HAIC were successfully performed in 8 cases,with technical success rate of 100%.One month after the first b-HAIC,shunt flow of HAPF decreased or even completely closed,with effective rate of 100%.After 2-3 times b-HAIC,the objective response rate(ORR)and disease control rate(DCR)of HCC was 87.50%(7/8)and 100%(8/8),respectively.Grade 1-3 adverse events were observed in all 8 cases,mainly presented as abdominal pain(7/8,87.50%)and transient elevation of transaminases and all alleviated after rest or symptomatic treatments.No grade 4-5 adverse event occurred.Conclusion b-HAIC was effective and relatively safe for treating unresectable HCC complicated with HAPF.
